Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting

Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports Jg. 13; H. 1; S. 9584 - 11
Hauptverfasser: Belaroussi, Yaniss, Bouteiller, Fanny, Bellera, Carine, Pasquier, David, Perol, Maurice, Debieuvre, Didier, Filleron, Thomas, Girard, Nicolas, Schott, Roland, Mathoulin-Pélissier, Simone, Martin, Anne-Laure, Cousin, Sophie
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 13.06.2023
Nature Publishing Group
Nature Portfolio
Schlagworte:
631/67
631/67/1612
631/67/1612/1350
Carcinoma, Non-Small-Cell Lung - drug therapy
Chemotherapy
Humanities and Social Sciences
Humans
Immunotherapy
Life Sciences
Lung cancer
Lung Neoplasms - drug therapy
Metastases
Metastasis
multidisciplinary
Non-small cell lung carcinoma
Patients
Santé publique et épidémiologie
Science
Science (multidisciplinary)
Small cell lung carcinoma
Survival
Time-to-Treatment
Carcinoma
Time-to-Treatment
Immunotherapy
Humans
Non-Small-Cell Lung
Patients
Lung Neoplasms
ISSN:2045-2322, 2045-2322
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015–2019. The impact of treatment on rwPFS/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63 years median age). Median OS in immunotherapy group was 16.4 months (95%CI [14.1–NR]) and was higher than in chemotherapy group (11.6 months; 95%CI [11.0–12.2]). Improved OS was observed for the immunotherapy group after 3 months for subjects with performance status 0–1 (HR = 0.59; 95%CI [0.42–0.83], p < 0.01). The associations between rwPFS and TNT with OS were close ( τ =0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-36623-1